Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting

Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an an...

Full description

Saved in:
Bibliographic Details
Published inOncoimmunology Vol. 2; no. 4; p. e23700
Main Authors Birklé, Stéphane, Desselle, Ariane, Chaumette, Tanguy, Gaugler, Marie-Hélène, Cochonneau, Denis, Fleurence, Julien, Dubois, Nolwenn, Hulin, Philippe, Aubry, Jacques, Paris, François
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.04.2013
Landes Bioscience
Subjects
antiangiogenic therapy
antibody
Author's View
Gb3
glycosphingolipid
Gb3
glycosphingolipid
antiangiogenic therapy
antibody
Online AccessGet full text
ISSN2162-402X
2162-4011
2162-402X
DOI10.4161/onci.23700

Cover

Abstract Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
AbstractList Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial cells. We proposed globotriaosylceramide (Gb3) as a viable alternative target for antiangiogenic therapies. In this setting, we developed an anti-Gb3 antibody and validated its therapeutic efficacy in metastatic tumor models.
Author Hulin, Philippe
Aubry, Jacques
Gaugler, Marie-Hélène
Birklé, Stéphane
Cochonneau, Denis
Fleurence, Julien
Paris, François
Dubois, Nolwenn
Desselle, Ariane
Chaumette, Tanguy
Author_xml – sequence: 1
  givenname: Stéphane
  surname: Birklé
  fullname: Birklé, Stéphane
– sequence: 2
  givenname: Ariane
  surname: Desselle
  fullname: Desselle, Ariane
– sequence: 3
  givenname: Tanguy
  surname: Chaumette
  fullname: Chaumette, Tanguy
– sequence: 4
  givenname: Marie-Hélène
  surname: Gaugler
  fullname: Gaugler, Marie-Hélène
– sequence: 5
  givenname: Denis
  surname: Cochonneau
  fullname: Cochonneau, Denis
– sequence: 6
  givenname: Julien
  surname: Fleurence
  fullname: Fleurence, Julien
– sequence: 7
  givenname: Nolwenn
  surname: Dubois
  fullname: Dubois, Nolwenn
– sequence: 8
  givenname: Philippe
  surname: Hulin
  fullname: Hulin, Philippe
– sequence: 9
  givenname: Jacques
  surname: Aubry
  fullname: Aubry, Jacques
– sequence: 10
  givenname: François
  surname: Paris
  fullname: Paris, François
  email: francois.paris@inserm.fr
BackLink https://www.ncbi.nlm.nih.gov/pubmed/23734323$$D View this record in MEDLINE/PubMed
BookMark eNptkV9rFTEQxYO02Fr74geQfRThtvmfuy-CFKsXCr604FvI7s5uI9lMTbKV--3N7a2lSuclA_mdM8OcN-QgYgRC3jF6Jplm5xh7f8aFofQVOeZM85Wk_MfBs_6InOb8k9bSVGnRviZHlRdScHFMNpt46ztfPMYGx6YsM6bGxcnjBBGyz023baaAHZbkHeZt6CG52Q_Q-HleIhaXJig-Tm_J4ehChtPH94TcXH65vvi2uvr-dXPx-WrVCyXLapQGlOqU0bwTrRx5a1rHBwaSd4obCo4JB2Y9sPXYj7QdBBgqZSXNIBzV4oR82vveLd0MQw-xJBfsXfKzS1uLztt_f6K_tRPeW6GVVK2oBh8eDRL-WiAXO_vcQwguAi7ZsjXXylC9lhV9_3zW05C_96vAxz3QJ8w5wfiEMGp3-dhdPvYhnwrT_-DeF7c7fd3Th5clai_xccQ0u9-YwmCL2wZMY3IVzFa8oPsDg5mnpA
CitedBy_id crossref_primary_10_3390_toxins13060378
crossref_primary_10_1007_s00018_022_04524_7
crossref_primary_10_3390_cancers16051060
crossref_primary_10_3390_ijms20143564
crossref_primary_10_3390_md23030127
crossref_primary_10_1002_jcp_25072
Cites_doi 10.1021/cr0100446
10.2174/1871520610909040381
10.1371/journal.pone.0045423
10.1128/CMR.11.3.450
10.1161/01.RES.0000185327.45463.A8
ContentType Journal Article
Copyright Copyright © 2013 Landes Bioscience 2013
Copyright_xml – notice: Copyright © 2013 Landes Bioscience 2013
DBID 0YH
AAYXX
CITATION
NPM
7X8
5PM
DOI 10.4161/onci.23700
DatabaseName Taylor & Francis Open Access
CrossRef
PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
PubMed
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
PubMed
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 0YH
  name: Taylor & Francis Open Access
  url: https://www.tandfonline.com
  sourceTypes: Publisher
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2162-402X
ExternalDocumentID PMC3654593
23734323
10_4161_onci_23700
10923700
Genre Other
Journal Article
GroupedDBID 00X
0YH
53G
AAKDD
ABDBF
ABUPF
ACENM
ACGFS
ACUHS
ADBBV
ADCVX
AENEX
AIJEM
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BABNJ
BLEHA
CCCUG
DEAQA
DGEBU
DGFLZ
EBD
EBS
EJD
EUPTU
GROUPED_DOAJ
H13
HYE
KRBQP
KSSTO
KTTOD
KWAYT
KYCEM
M4Z
O9-
OK1
OVD
RPM
TDBHL
TEORI
TFL
TFW
TNTFI
4.4
AAYXX
CITATION
LJTGL
TTHFI
NPM
7X8
EMOBN
5PM
ID FETCH-LOGICAL-c354t-f47e55b5762b394f2979a2d1e42b5270ea13ae78d18fcf09d3e704494f7d3a063
IEDL.DBID 0YH
ISSN 2162-402X
2162-4011
IngestDate Thu Aug 21 13:57:04 EDT 2025
Thu Sep 04 23:56:06 EDT 2025
Thu Apr 03 06:57:51 EDT 2025
Tue Jul 01 02:07:39 EDT 2025
Thu Apr 24 23:10:49 EDT 2025
Wed Dec 25 09:05:17 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 4
Keywords Gb3
glycosphingolipid
antiangiogenic therapy
antibody
Language English
License open-access: http://creativecommons.org/licenses/by-nc/3.0/: This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c354t-f47e55b5762b394f2979a2d1e42b5270ea13ae78d18fcf09d3e704494f7d3a063
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors equally contributed to the manuscript.
OpenAccessLink https://www.tandfonline.com/doi/abs/10.4161/onci.23700
PMID 23734323
PQID 1826570684
PQPubID 23479
ParticipantIDs pubmed_primary_23734323
crossref_primary_10_4161_onci_23700
pubmedcentral_primary_oai_pubmedcentral_nih_gov_3654593
crossref_citationtrail_10_4161_onci_23700
proquest_miscellaneous_1826570684
informaworld_taylorfrancis_310_4161_onci_23700
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 4/1/2013
2013-04-00
2013-Apr-01
20130401
PublicationDateYYYYMMDD 2013-04-01
PublicationDate_xml – month: 04
  year: 2013
  text: 4/1/2013
  day: 01
PublicationDecade 2010
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Oncoimmunology
PublicationTitleAlternate Oncoimmunology
PublicationYear 2013
Publisher Taylor & Francis
Landes Bioscience
Publisher_xml – name: Taylor & Francis
– name: Landes Bioscience
References R2
R3
Paton JC (R4) 1998; 11
R5
R1
References_xml – ident: R2
  doi: 10.1021/cr0100446
– ident: R1
  doi: 10.2174/1871520610909040381
– ident: R3
  doi: 10.1371/journal.pone.0045423
– volume: 11
  start-page: 450
  year: 1998
  ident: R4
  publication-title: Clin Microbiol Rev
  doi: 10.1128/CMR.11.3.450
– ident: R5
  doi: 10.1161/01.RES.0000185327.45463.A8
SSID ssj0000605639
Score 1.97849
Snippet Current antiangiogenic immunotherapeutic strategies mainly focus on the blockade of circulating cytokines or receptors that are overexpressed by endothelial...
SourceID pubmedcentral
proquest
pubmed
crossref
informaworld
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage e23700
SubjectTerms antiangiogenic therapy
antibody
Author's View
Gb3
glycosphingolipid
Title Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
URI https://www.tandfonline.com/doi/abs/10.4161/onci.23700
https://www.ncbi.nlm.nih.gov/pubmed/23734323
https://www.proquest.com/docview/1826570684
https://pubmed.ncbi.nlm.nih.gov/PMC3654593
Volume 2
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1NT9wwEB0hUKVeEG0pLG1RKrj0EHD8ESdHKF0tleAEEj1FduxApCVGu9nD_vvOJLsrFu2FW6SMlWjGzrxxxu8BnBptqyxLVMx9yWKZOhvbTJuYKedwgslEWtrQv7lNR_fy74N62IJ0eRaG2iqphq56oojuW02L29hOgYTg-HloyvqMC82wVN_hGpMMzmP2b7TaW2GI0THz9mykb4as5Z81dtJNGPNtq-Sr3DPcg90FaIwu-ih_gi3ffIYPvYzk_AtcXzdPte16r6JQRe3sOUwi0zzW4ZG-ZPU0svOImD8CaXSE6Xxc-ol5rp2PajoeEvp2cExi-3A__HP3exQvJBLiUijZxpXUXimLRQO3IpcVz3VuuEu85FZxzbxJhPE6c0lWlRXLnfCaSYmW2gmD8OQrbDeh8YcQCczUuVXWKCz6nBJ4qR2TJjPCOgzdAH4tHVeUC_5wkrEYF1hHkJMLcnLROXkAJyvbl541Y6PV2Wv_F223R1H1giKF2DTg5zJCBa4C-rVhGh9m04KqJKVZmskBHPQRWz0Yh9LpWTEAvRbLlQExbK_faeqnjmlbpAgwc3H03hf9Bh95J5tBHT7fYbudzPwPBC-tPe5m6jHsXFxeXQ7_A2WI898
linkProvider Taylor & Francis
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1LT9wwELYQCLUXBPTB0gJB7aWHUCe2Y-dYIVa7vE4g0ZNlxw5EghjtZg_77zuTZFcs2ktvkTJWohnb8814_A0hP420pVKJiFNf0JhnzsZWSRNT4RxMMJ5wiwn9m9tsdM8vH8RDn7qY9mWVGEOXHVFEu1fj4sZkNK5wxOO_Q11UZymTFGL1LaFUhhOc_h0tkysUQDq43o6O9N2QFQe0Qk-6DmS-r5V843yGu2SnR43Rn87Me2TD1_tku-sjOf9ExuP6qbJt8VUUyqiZvYRJZOrHKjziVlZNIzuPkPojYJOOMJ0_F35iXirnowrvh4SuHhy82GdyP7y4Ox_FfY-EuGCCN3HJpRfCQtSQWpbzMs1lblKXeJ5akUrqTcKMl8olqixKmjvmJeUcJKVjBvDJF7JZh9ofkIiBq86tsEZA1OcEg0fpKDfKMOvAdgPya6E4XfQE4tjH4llDIIFK1qhk3Sp5QH4sZV872oy1Umdv9a-bNklRdh1FNFs34HRhIQ3LAM82TO3DbKoxTBKSZooPyNfOYssPw1C8PssGRK7YcimAFNurb-rqqaXaZhkgzJwd_u-PnpAPo7uba309vr36Rj6mbQ8NLPf5TjabycwfAZJp7HE7a_8B8FD14g
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9swDCaKDh12GfZu9ug8bJcd3MmWZNnHYWuQdFuxwwp0J0GypNZAaxWJc8i_H2knQVPkspsBk7BBSuJHifoI8MkoG8oyk2nua5aKwtnUlsqkTDqHA0xkwtKG_q-zYnIuTi_kxR4U67swVFZJOXQYiCL6tZom960LNMEJjn-Jbd0c51wxTNUfyBIxOY5j9ney2VthiNEx8g5spPdUtuLPFjvpLox5v1TyTuwZP4HHK9CYfB28_BT2fPsMDoY2ksvnMJ22V43ta6-SGJJucRNniWkvm3hJK1kzT-wyIeaPSD064nx5XfuZuWmcTxq6HhKHcnAMYi_gfHzy59skXbVISGsuRZcGobyUFpOG3PJKhLxSlcld5kVuZa6YNxk3XpUuK0MdWOW4V0wIlFSOG4QnL2G_ja0_hIRjpK6stEZi0uckx0flmDCl4dah60bweW04Xa_4w6mNxbXGPIKMrMnIujfyCD5uZG8H1oydUsd37a-7fo8iDA1FNN-l8GHtIY2zgI42TOvjYq4pS5KKFaUYwavBY5sPoyrdnuUjUFu-3AgQw_b2m7a56pm2eYEAs-Kv__dH38PD39_H-uf07McbeJT3HTSo2Oct7HezhX-HOKazR_2g_Qd9kfUL
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Inhibition+of+tumor+angiogenesis+by+globotriaosylceramide+immunotargeting&rft.jtitle=Oncoimmunology&rft.au=Birkl%C3%A9%2C+St%C3%A9phane&rft.au=Desselle%2C+Ariane&rft.au=Chaumette%2C+Tanguy&rft.au=Gaugler%2C+Marie-H%C3%A9l%C3%A8ne&rft.date=2013-04-01&rft.issn=2162-402X&rft.eissn=2162-402X&rft.volume=2&rft.issue=4&rft.spage=e23700&rft_id=info:doi/10.4161%2Fonci.23700&rft.externalDBID=n%2Fa&rft.externalDocID=10_4161_onci_23700
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2162-402X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2162-402X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2162-402X&client=summon